anti-PD1

anti-PD1 Approved for Lung Cancer!

Anti-PD1, which is one of the more potent checkpoint blockade treatments with very mild side effects, has just been approved for lung cancer.

Anti-PD1 Immunotherapy in Hodgkin's Lymphoma: Why It Works and Future Directions.

Hodgkin's lymphoma and anti-PD1 immunotherapyThere have been remarkable results of anti-PD1 causing remissions in heavily pretreated Hodgkin's Lymphoma patients.

Here we examine why this cancer immunotherapy can change the way Hodgkin's Lymphoma patients are treated in the future.

Hodgkin's Lymphoma is a good target for anti-PD1.

Anti-PD1 Immunotherapy in Hodgkin's Lymphoma: Clinical Trial Results (Dec 2014)

Hodgkin's Lymphoma anti-PD1 phase 1b clinical trial resultsAnti-PD1 treatments are showing tremendous results for Hodgkin's Lymphoma patients who have not responded to conventional treatments.
 

The results are coming out at the American Society of Hematology (ASH) conference, December 2014 and creating great excitement.

 

Anti-PD1 Immunotherapy in Lung Cancer: Video and Summary

This is an excellent video explaining immunotherapy in lung cancer, primarily focusing on anti-PD1.

This video was published November 4, 2014 by Global Resource for Advancing Cancer Education (GRACE).

Dr. Jack West (Swedish Cancer Center, Seattle) moderates this discussion with Dr. Julie Brahmer (John Hopkins, Baltimore) and Dr. Ben Creelan (Moffitt Cancer Center, Tampa).

Syndicate content